ABSTRACT
INTRODUCTION T
HE PROPER MANAGEMENT of lower caliceal calculi is one of the most controversial subjects among the stone disease centers. Although extracorporeal shockwave lithotripsy (SWL) has been the therapy of choice for most lower pole renal stones, in the review of Lingeman and colleagues, 1 the overall stone-free rate was only 59% after SWL. This high failure rate is attributable mainly to retained stone fragments, which may reaggregate or constitute a nucleus for new stone formation. 2 It has been reported that appropriate medical treatment initiated after SWL, even in the presence of residual calculi, might control active stone disease by decreasing the saturation of stone-forming substances or enhancing inhibitory activity. 3 Potassium citrate therapy has gained increasing attention in the prevention of calcium oxalate nephrolithiasis. Ettinger and colleagues 4 demonstrated that nonselective treatment with potassium-magnesium citrate prevents calcium nephrolithiasis.
In this study, we prospectively evaluated the effect of potassium citrate therapy on stone recurrences and residual fragments after SWL for lower caliceal calcium oxalate urolithiasis.
PATIENTS AND METHODS
One hundred ten patients who underwent SWL monotherapy with the Dornier MPL 9000 lithotripter because of lower caliceal stones and who were stone free or who had residual Departments of 1 Urology and 2 Biochemistry, Faculty of Medicine, University of Ankara, Ankara, Turkey. stone fragments ,5 mm in diameter on plain abdominal films and renal ultrasound scan 4 weeks later were enrolled in the study. The maximum diameter of the treated stones ranged from 5 to 15 mm (mean 9.2 6 2.7 mm.). For patients who had residual stones .5 mm, secondary SWL treatment was recommended.
The average patient age was 41.7 years (range 18.3-62.5; median 41.2 years). All patients had documented calcium oxalate stones without urinary tract infection. They had no anatomic abnormality of the urinary tract, no history of urologic surgery or urolithiasis, and no definitive metabolic disease such as hyperparathyroidism or renal tubular acidosis. Thus, only patients with simple renal lithiasis in the presence of normal renal morphology and function were included.
At the initial admission, all patients underwent a detailed evaluation, including urinanalysis and 24-hour urine samples on a random dietary regimen to determine volume, calcium, citrate, uric acid, and creatinine clearance. Urinanalysis showed that 34 patients had urinary citrate levels ,320 mg per day (hypocitraturia), and 18 patients had calciuria .300 mg per day. Sixteen patients had urinary uric acid levels .600 mg per day in two or three collected samples.
Four weeks after SWL, abdominal plain films and ultrasound scans were evaluated, and patients who were stone free (N 5 56) or who had residual stones (N 5 34) were independently randomized into two subgroups that were matched for sex, age, and urinary values of citrate, calcium and uric acid. One group was given oral potassium citrate 60 mEq per day, and the other group served as controls. Potassium citrate tablets 5 mEq were administered in three doses after meals. Both the citrate-treated group and the controls were advised to have a high fluid intake to achieve a minimum daily urine output of 2.1 L and to avoid excess oxalate-rich foods and salty foods. They were instructed to limit their daily meat intake to 8 ounces or less, to substitute whole wheat bread for white bread, and to eat natural fiber cereals. Table 1 summarizes the characteristics of the patient groups.
Twelve months after the initial treatment, patients were reevaluated. Prelithotripsy abdominal radiographs and ultrasound scans as well as postlithotripsy abdominal radiographs and ultrasound scans were reviewed without knowledge of patient allocation. Films at 4 weeks after SWL were compared for the chance in the size of residual stones, appearance of new stones, or disappearance of stones. Stone recurrence was defined as passage of a stone that had not been recognized, any newly formed stone, or size increment of a residual fragment remaining after initial SWL by .2 mm.
Remission rates and growth rates between groups during the post-SWL period were compared using Fisher's exact test.
RESULTS
Twenty patients were excluded from the analysis because of noncompliance with follow-up (10 patients), epigastric discomfort (6 patients), and reluctance to receive medication (4 patients). Therefore, statistical evaluation was performed for 90 patients. Compliance with citrate therapy was determined by evaluating urinary excretion of citrate and potassium and was good in all patients. In the 46 citrate-treated patients, urinary SOYGÜR ET AL. 150 The stone recurrence rate at 12 months in the stone-free group who were on citrate therapy (0 of 28 cases) was significantly (P , 0.05) less than in the control patients (8 of 28 cases; 28.5%). In patients with residual stones, the fragments disappeared in 8 of the 18 patients (45.5%) and remained the same size in 10 of the 18 patients (54.5%) who continued medical treatment. In the control arm, only 2 patients (12.5%) demonstrated disappearance of residual stone fragments (P , 0.05), whereas 10 of 16 patients (62.5%) demonstrated increments in the size of the residual fragments. In 4 patients (25%), residual fragments remained unchanged. The stone activity at 12 months' follow-up is summarized in Table 2 .
DISCUSSION
Although SWL is the treatment of choice for approximately 90% of caliceal calculi, review of the literature nearly uniformly describes a lower stone-free rate for lower caliceal stones than for those in middle and superior calices. 5 In the study of Küpeli and associates, 6 the overall stone-free rate for lower pole calculi was 53.3%. Besides the numerous factors such as stone burden, stone composition, and anatomic abnormalities that have been demonstrated to affect the result of SWL, stone location seems to be an important factor. 7 Lower caliceal location results in retention of fragments within the kidney after SWL, and these can act as a nidus for further stone formation. This is the major shortcoming of this form of stone treatment. Although patients with residual concrements of 5 mm or larger are treated again with SWL, small stone fragments (,5 mm) are considered by some to be clinically insignificant. However, studies of Streem and colleagues 8 have noted an increase in stone formation, growth of residual fragments, or symptomatic episodes in patients with residual calculi (,5 mm) after SWL. To improve the success rate of SWL, different applications have been proposed for lower pole nephrolithiasis, such as inversion therapy, direct irrigation of the lower calices during SWL, or forced diuresis with percussion of the flank area. [7] [8] [9] [10] On the other hand, the efficacy of the medical approach in controlling stone disease is now fairly well established. Many studies have been performed to examine the efficacy of oral citrate therapy in patients with calcium oxalate stones. Citrate complexes with calcium, thereby decreasing urinary saturation, and has been shown to inhibit the aggregation of calcium oxalate crystals. 11 Because growth of residual stones and possible formation of new calculi may be inevitable, prophylactic medical therapy should be considered to prevent new stone formation after SWL treatment.
Two recent studies support the role of medical treatment following stone removal, especially when residual fragments are present. 3, 12 In the study of Cicerrelo and coworkers 12 there was a 75% reduction in the size of calcium stone fragments in those patients receiving sodium citrate. However, 32% of the patients receiving conservative measures had clearance of their stone fragments. In an open trial, Fine et al 3 offered drug treatments to some and no treatment to others among patients completing SWL. Stone formation was substantially reduced, by 91%, in the treated group but continued unabated in the untreated group. In patients with residual fragments after SWL, medical therapy produced an 81% improvement in the stone-free rate.
Our study specifically addressed the ability of potassium citrate to inhibit calcium oxalate crystal nucleation and growth on stone fragments remaining after SWL for lower caliceal calculi, for which SWL has much lower efficacy. In patients who were stone free after SWL and receiving medical treatment, the stone recurrence rate at 12 months was 0, whereas untreated patients showed a 28.5% stone recurrence rate (P , 0.05). Similarly, in the residual fragment group, the medically treated patients had a significantly greater remission rate than the untreated patients (44.5 v 12.5%; P , 0.05). Among the patients with residual stone fragments, none showed an increase in stone burden during medical treatment after SWL compared with 62.5% of those not having medical treatment (P , 0.01). Because patients who were stone free or had residual fragments after SWL were divided randomly into the citrate therapy and control groups, urine levels of citrate, calcium, and uric acid were not considered significant variables during the reevaluation of patients at 12 months' follow-up.
CONCLUSION
Although our length of follow-up is shorter than the common practice of 36 months in the literature, the preliminary results clearly demonstrated that potassium citrate therapy significantly alleviated calcium oxalate stone activity after SWL for lower pole stones in patients who were stone free at 12 months' follow-up. An important result was the beneficial effect of medical treatment on stone activity among patients with residual calculi after SWL. Citrate treatment significantly ameliorated the outcome of these residual fragments by decreasing growth or agglomeration. More importantly, such therapy may be allowing spontaneous passage and thus increasing the clearance rate.
